Current Support
Regeneron Pharmaceuticals, Inc., “Opportunity to Reach Individuals with Genetic dyslipidemia during Infancy and the Newborn period to find Familial Hypercholesterolemia (ORIGIN-FH)” (2025-2029). Peterson, PI
FH Foundation & Duke University, “The Familial Hypercholesterolemia Foundation CASCADE-FH Registry” (2016-ongoing). Peterson, Site PI
Completed Support
NIH/NICHD (R21 HD102793), “Biochemical and molecular newborn screening for familial hypercholesterolemia” (2021-2024). Peterson, PI
Novartis, “Two part, double-blind inclisiran versus placebo, followed by open-label inclisiran, randomized multicenter study to evaluate safety, tolerability, and efficacy of inclisiran (ORION)” (2021-2024). Peterson, Site PI
New England Research Institutes, “The Dyslipidemia of Obesity Intervention in Teens (DO IT!) Trial” (2019-2024). Peterson, Site PI
Wisconsin Partnership Program (WPP), “Improved diagnosis of pediatric familial hypercholesterolemia through the Wisconsin Pediatric Lipid Consortium (WPLC)” (2017-2019), Peterson, PI